The author regrets to announce that the declarations of interest, listed in the above article (McCleery et al. Reference McCleery, Green, Hellemann, Baade, Gold, Keefe, Kern, Mesholam-Gately, Seidman, Subotnik, Ventura and Nuechterlein2015) contained an omission. The correct and complete version of the declaration of interest is given below.
M. F. Green and K. H. Nuechterlein are officers within MATRICS Assessment, Inc., the non-profit publisher of the MCCB, but do not receive any financial remuneration for their respective roles. M. F. Green has been a consultant to AbbVie, DSP, EnVivo, FORUM Pharmaceuticals, and Roche, and he is on the scientific advisory board of Mnemosyne. He has received research funds from Amgen (20130132). J. M. Gold receives royalty payments from The Brief Assessment of Cognition in Schizophrenia (BACS) and has been a consultant to Amgen, Hoffman-LaRoche, Lundback, and Pfizer. R. S. Kern has been an officer for MATRICS Assessment, Inc. and received financial compensation for his role within the non-profit organization. K. L. Subotnik has received research funding from Janssen Scientific Affairs, LLC, and Genentech, Inc., through grants to K. H. Nuechterlein and J. Ventura. K. L. Subotnik is a consultant to Otsuka America Pharmaceutical, Inc. J. Ventura has received funding from Genentech, Inc. (C4-150335). He has served as a consultant to Brain Plasticity, Inc., and Boehringer-Ingelheim GmbH. K. H. Nuechterlein has received research grants from Janssen Scientific Affairs (R092670SCH4005; RIS-NAP-4009), Genentech (ML28264), and Posit Science (BPI-1000-11) and has been a consultant to Otsuka, Janssen Scientific Affairs, and Genentech. R.S.E. Keefe currently or in the past 3 years has received investigator-initiated research funding support from the Department of Veteran's Affairs, Feinstein Institute for Medical Research, GlaxoSmithKline, National Institute of Mental Health, Novartis, Psychogenics, Research Foundation for Mental Hygiene, Inc., and the Singapore National Medical Research Council. He currently or in the past 3 years has received honoraria, served as a consultant, or advisory board member for Abbvie, Akebia, Amgen, Asubio, AviNeuro/ChemRar, BiolineRx, Biogen Idec, Biomarin, Boehringer-Ingelheim, Eli Lilly, EnVivo/FORUM, GW Pharmaceuticals, Janssen, Lundbeck, Merck, Minerva Neurosciences, Inc., Mitsubishi, Novartis, NY State Office of Mental Health, Otsuka, Pfizer, Reviva, Roche, Sanofi/Aventis, Shire, Sunovion, Takeda, Targacept, and the University of Texas South West Medical Center. R.S.E. Keefe receives royalties from the BACS testing battery, the MATRICS Battery (BACS Symbol Coding) and the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). He is also a shareholder in NeuroCog Trials, Inc. and Sengenix. Drs. McCleery, Hellemann, Baade, Mesholam-Gately, and Seidman declare they have no conflicts of interest.